ABSTRACT
Stroke remains the leading cause of disability and the third leading cause of death. Despite advances in treatment, the early and later outcomes remain poor with a high rate of death and or disability. Strategies for prevention have assumed a central role. Given the close relationship between advancing age, atrial fibrillation, and increasing stroke, there is great interest in this large specific population of patients. Although warfarin has been the cornerstone of therapy for stroke prevention in patients with atrial fibrillation, it is often not used because of absolute or relative contraindications, or is ineffective because of poor control of the international normalized ratio (INR). The relative risk-benefit ratio of stroke prevention versus bleeding hazard plays a central role in therapeutic decisions. New pharmacologic approaches have been studied, most recently direct thrombin inhibitors. These drugs may be associated with less bleeding than warfarin, although there continues to be incremental bleeding risk over a patient's lifetime. In patients with nonvalvular atrial fibrillation, device strategies are being tested. These are based upon the information that in such patients, stroke arises from thrombus in the left atrial appendage in 90% of cases. Left atrial appendage occlusion has now been tested in a randomized clinical trial. In this trial, device closure was found to be noninferior to warfarin for prevention of all-cause stroke, cardiac death, and systemic embolization. There was an early safety hazard typically related to periprocedural pericardial effusions; however, subsequent experience has continued to document excellent efficacy and improved safety profiles. New randomized trials and registries continue to explore the potential for device placement as an alternative to anticoagulant therapy for stroke prevention in this group of patients.
KEYWORDS
Atrial fibrillation - stroke prevention - left atrial appendage closure
REFERENCES
-
1
Cooper N J, Sutton A J, Lu G, Khunti K.
Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation.
Arch Intern Med.
2006;
166
(12)
1269-1275
-
2
Singer D E, Chang Y, Fang M C et al..
Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study.
Circ Cardiovasc Qual Outcomes.
2009;
2
(4)
297-304
-
3
Fang M C, Go A S, Chang Y, Borowsky L, Pomernacki N K, Singer D E. ATRIA Study Group .
Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation.
J Am Coll Cardiol.
2008;
51
(8)
810-815
-
4
Miyasaka Y, Barnes M E, Gersh B J et al..
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.
Circulation.
2006;
114
(2)
119-125
-
5
Benjamin E J, Levy D, Vaziri S M, D'Agostino R B, Belanger A J, Wolf P A.
Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.
JAMA.
1994;
271
(11)
840-844
-
6
Stewart S, Hart C L, Hole D J, McMurray J J.
Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study.
Heart.
2001;
86
(5)
516-521
-
7
Lloyd-Jones D M, Wang T J, Leip E P et al..
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study.
Circulation.
2004;
110
(9)
1042-1046
-
8
Garcia D A, Hylek E.
Reducing the risk for stroke in patients who have atrial fibrillation.
Cardiol Clin.
2008;
26
(2)
267-275, vii
-
9
Sherman D G, Kim S G, Boop B S National Heart, Lung, and Blood Institute AFFIRM Investigators et al.
Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study.
Arch Intern Med.
2005;
165
(10)
1185-1191
-
10
Ezekowitz M D, Bridgers S L, James K E Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators et al.
Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation.
N Engl J Med.
1992;
327
(20)
1406-1412
-
11
Hart R G, Pearce L A, Aguilar M I.
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.
Ann Intern Med.
2007;
146
(12)
857-867
-
12
Go A S, Hylek E M, Chang Y et al..
Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?.
JAMA.
2003;
290
(20)
2685-2692
-
13
Gage B F, Boechler M, Doggette A L et al..
Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation.
Stroke.
2000;
31
(4)
822-827
-
14
Anderson D C, Kappelle L J, Eliasziw M, Babikian V L, Pearce L A, Barnett H J.
Occurrence of hemispheric and retinal ischemia in atrial fibrillation compared with carotid stenosis.
Stroke.
2002;
33
(8)
1963-1967
-
15
Crandall M A, Bradley D J, Packer D L, Asirvatham S J.
Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies.
Mayo Clin Proc.
2009;
84
(7)
643-662
-
16
Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny R A.
Prevalence of atrial fibrillation and eligibility for anticoagulants in the community.
Lancet.
1998;
352
(9135)
1167-1171
-
17
Smith W S, Sung G, Starkman S MERCI Trial Investigators et al.
Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial.
Stroke.
2005;
36
(7)
1432-1438
-
18
Penumbra Pivotal Stroke Trial Investigators .
The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease.
Stroke.
2009;
40
(8)
2761-2768
-
19
Wolf P A, Abbott R D, Kannel W B.
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.
Stroke.
1991;
22
(8)
983-988
-
20
Lin H J, Wolf P A, Kelly-Hayes M et al..
Stroke severity in atrial fibrillation. The Framingham Study.
Stroke.
1996;
27
(10)
1760-1764
-
21
Fisher C M.
Reducing risks of cerebral embolism.
Geriatrics.
1979;
34
(2)
59-61, 65–66
-
22
Petty G W, Brown Jr R D, Whisnant J P, Sicks J D, O'Fallon W M, Wiebers D O.
Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence.
Stroke.
2000;
31
(5)
1062-1068
-
23
Gage B F, Waterman A D, Shannon W, Boechler M, Rich M W, Radford M J.
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.
JAMA.
2001;
285
(22)
2864-2870
-
24
The Stroke Prevention in Atrial Fibrillation Investigators .
Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk.
Ann Intern Med.
1992;
116
(1)
6-12
-
25
Hylek E M, Singer D E.
Risk factors for intracranial hemorrhage in outpatients taking warfarin.
Ann Intern Med.
1994;
120
(11)
897-902
-
26
Hylek E M, Skates S J, Sheehan M A, Singer D E.
An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.
N Engl J Med.
1996;
335
(8)
540-546
-
27
The European Atrial Fibrillation Trial Study Group .
Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia.
N Engl J Med.
1995;
333
(1)
5-10
-
28
Epstein R S, Moyer T P, Aubert R E et al..
Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).
J Am Coll Cardiol.
2010;
55
(25)
2804-2812
-
29
Singer D E, Albers G W, Dalen J E American College of Chest Physicians et al.
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed).
Chest.
2008;
133
(6, Suppl)
546S-592S
-
30
Singer D E, Chang Y, Fang M C et al..
The net clinical benefit of warfarin anticoagulation in atrial fibrillation.
Ann Intern Med.
2009;
151
(5)
297-305
-
31
Connolly S J, Pogue J, Hart R G ACTIVE Investigators et al.
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
N Engl J Med.
2009;
360
(20)
2066-2078
-
32
Connolly S J, Ezekowitz M D, Yusuf S RE-LY Steering Committee and Investigators et al.
Dabigatran versus warfarin in patients with atrial fibrillation.
N Engl J Med.
2009;
361
(12)
1139-1151
-
33
Lip G YH, Edwards S J.
Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis.
Thromb Res.
2006;
118
(3)
321-333
-
34
Connolly S J, Pogue J, Hart R G ACTIVE Writing Group of the ACTIVE Investigators et al.
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Lancet.
2006;
367
(9526)
1903-1912
-
35
Sievert H, Lesh M D, Trepels T et al..
Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience.
Circulation.
2002;
105
(16)
1887-1889
-
36
Bayard Y L, Omran H, Neuzil P et al..
PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study.
EuroIntervention.
2010;
6
(2)
220-226
-
37
Block P C, Burstein S, Casale P N et al..
Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study.
JACC Cardiovasc Interv.
2009;
2
(7)
594-600
-
38
Holmes D R, Reddy V Y, Turi Z G PROTECT AF Investigators et al.
Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.
Lancet.
2009;
374
(9689)
534-542
-
39
Sick P B, Schuler G, Hauptmann K E et al..
Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation.
J Am Coll Cardiol.
2007;
49
(13)
1490-1495
-
40
Hara H, Virmani R, Holmes Jr D R et al..
Is the left atrial appendage more than a simple appendage?.
Catheter Cardiovasc Interv.
2009;
74
(2)
234-242
-
41
Yan B P, Kiernan T J, Gonzales-Cruz I, Lam Y Y.
Left atrial appendage-occluding devices for stroke prevention in patients with nonvalvular atrial fibrillation.
Expert Rev Med Devices.
2009;
6
(6)
611-620
-
42
Cruz-Gonzalez I, Cubeddu R J, Sanchez-Ledesma M et al..
Left atrial appendage exclusion using an Amplatzer device.
Int J Cardiol.
2009;
134
(1)
e1-e3
-
43
Bayard Y L, Ostermayer S H, Sievert H.
Transcatheter occlusion of the left atrial appendage for stroke prevention.
Expert Rev Cardiovasc Ther.
2005;
3
(6)
1003-1008
-
44
Meier B, Palacios I, Windecker S et al..
Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation.
Catheter Cardiovasc Interv.
2003;
60
(3)
417-422
-
45
Blackshear J L, Odell J A.
Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation.
Ann Thorac Surg.
1996;
61
(2)
755-759
-
46
Aberg H.
Atrial fibrillation. I. A study of atrial thrombosis and systemic embolism in a necropsy material.
Acta Med Scand.
1969;
185
(5)
373-379
-
47
Veinot J P, Harrity P J, Gentile F et al..
Anatomy of the normal left atrial appendage: a quantitative study of age-related changes in 500 autopsy hearts: implications for echocardiographic examination.
Circulation.
1997;
96
(9)
3112-3115
-
48
Holmes Jr D R.
PROTECT AF Trial – Intermediate-term outcome.
J Am Coll Cardiol.
2010;
55
(10, Suppl A)
A181
-
49 Reddy B Y, Holmes D R, Doshi S K. The safety of percutaneous left atrial appendage closure: results from PROTECT AF and the continued access registry. In press
-
50
Healey J S, Crystal E, Lamy A et al..
Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke.
Am Heart J.
2005;
150
(2)
288-293
-
51
Blackshear J L, Johnson W D, Odell J A et al..
Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation.
J Am Coll Cardiol.
2003;
42
(7)
1249-1252
-
52
Friedman P A, Asirvatham S J, Dalegrave C et al..
Percutaneous epicardial left atrial appendage closure: preliminary results of an electrogram guided approach.
J Cardiovasc Electrophysiol.
2009;
20
(8)
908-915
-
53
Singh S M, Dukkipati S R, d'Avila A, Doshi S K, Reddy V Y.
Percutaneous left atrial appendage closure with an epicardial suture ligation approach: a prospective randomized pre-clinical feasibility study.
Heart Rhythm.
2010;
7
(3)
370-376
David R HolmesJr. M.D.
Professor of Medicine, Mayo Clinic
200 First Street SW, Rochester, MN 55905
eMail: holmes.david@mayo.edu
